Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes

Aims Among patients with acute coronary syndromes (ACS), those with diabetes mellitus (DM) are at particularly high risk of recurrent cardiovascular events and premature death. We aimed to provide a descriptive overview of unadjusted analyses of patient characteristics, ACS management, and outcomes up to 1 year after hospital admission for an ACS/index-ACS event, in patients with DM in contemporary registries in Europe. Methods and results A total of 10 registries provided data in a systematic manner on ACS patients with DM (total n =28 899), and without DM (total n= 97 505). In the DM population, the proportion of patients with ST-Segment Elevation Myocardial Infarction (STEMI) ranged from 22.1% to 64.6% (other patients had non-ST-Segment Elevation Myocardial Infarction (NSTEMI-ACS) or unstable angina). All-cause mortality in the registries ranged from 1.4% to 9.4% in-hospital; 2.8% to 7.9% at 30 days post-discharge; 5.1% to 10.7% at 180 days post-discharge; and 3.3% to 10.5% at 1 year post-discharge. Major bleeding events were reported in up to 3.8% of patients while in hospital (8 registries); up to 1.3% at 30 days (data from two registries only), and 2.0% at 1 year (one registry only). Registries differed substantially in terms of study setting, site, patient selection, definition and schedule of endpoints, and use of various P2Y12 inhibitors. In most, but not all, registries, event rates in DM patients were higher than in patients without DM. Pooled risk ratios comparing cohorts with DM vs. no DM were in-hospital significantly higher in DM for all-cause death (1.66; 95% CI 1.42-1.94), for cardiovascular death (2.33; 1.78 - 3.03), and for major bleeding (1.35; 1.21-1.52). Conclusion These registry data from real-life clinical practice confirm a high risk for recurrent events among DM patients with ACS, with great variation across the different registries.

[1]  J. Jukema,et al.  P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. , 2016, European heart journal. Cardiovascular pharmacotherapy.

[2]  G. Lemesle,et al.  A systematic review and meta-regression of temporal trends in the excess mortality associated with diabetes mellitus after myocardial infarction. , 2016, International journal of cardiology.

[3]  J. Jukema,et al.  Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. , 2016, European heart journal. Cardiovascular pharmacotherapy.

[4]  H. Ince,et al.  Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry , 2016, Vascular health and risk management.

[5]  H. Ince,et al.  MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel – the European MULTIPRAC Registry , 2015, European heart journal. Acute cardiovascular care.

[6]  J. López-Sendón,et al.  Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations. , 2015, European heart journal. Cardiovascular pharmacotherapy.

[7]  H. Thiele,et al.  Use, efficacy and safety of prasugrel in patients with ST segment elevation myocardial infarction scheduled for primary percutaneous coronary intervention in clinical practice. Results of the prospective ATACS-registry. , 2015, International journal of cardiology.

[8]  L. Räber,et al.  Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland , 2015, Heart.

[9]  C. Terkelsen,et al.  Underuse of an invasive strategy for patients with diabetes with acute coronary syndrome: a nationwide study , 2015, Open Heart.

[10]  A. Fernández-Ortiz,et al.  Prognosis and management of acute coronary syndrome in Spain in 2012: the DIOCLES study. , 2015, Revista espanola de cardiologia.

[11]  A. Zaman,et al.  Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel. , 2014, Cardiovascular therapeutics.

[12]  Marc P. Bonaca,et al.  American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therape , 2012, Circulation.

[13]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[14]  T. Lauer,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[15]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[16]  N. Rodondi,et al.  Swiss Cooperative Study Acute Coronary Syndromes and inflammation , 2011 .

[17]  S. Yusuf,et al.  Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial , 2010, The Lancet.

[18]  S. Stevens,et al.  Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial , 2010, European heart journal.

[19]  P. Erne,et al.  AMIS Plus: Swiss registry of acute coronary syndrome , 2010, Heart.

[20]  L. Wallentin,et al.  Abstract 1428: Statin Use After Myocardial Iinfarction Improves Survival in Nearly All With Renal Dysfunction: Data From the Swedish Web-system for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) , 2009 .

[21]  Insung Chung,et al.  Faculty Opinions recommendation of Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction , 2009 .

[22]  L. Wallentin,et al.  Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes. Data from the Euro Heart Survey ACS , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[23]  R. Giugliano,et al.  Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes , 2005, Circulation.

[24]  Á. Avezum,et al.  Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.

[25]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[26]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[27]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.

[28]  K. Mahaffey,et al.  ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .

[29]  Maarten L. Simoons,et al.  The third universal definition of myocardial infarction , 2013 .

[30]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[31]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[32]  F. Eberli,et al.  CORONARY ARTERY DISEASE Original Studies Impact of Diabetes Mellitus Status on Coronary Pathoanatomy and Interventional Treatment: Insights From the Euro Heart Survey PCI registry , 2011 .